MENU
DNTH
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

Dianthus Therapeutics (DNTH) Ownership - Who owns Dianthus Therapeutics?

Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies... Show more

Profile

Industry
N/A
Address
7 Times Square
Phone
+1 929 999-4055
Employees
53
Web
https://www.dianthustx.com

Details

Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
1.85B
P/E Ratio
3.24
Total Cash
402.61M
Projected Growth
N/A
Total Debt
1.29M
Revenue
3.08M
Risk (Beta)
N/A
Dividend Yield
N/A
Total Cash/Share
9.39
Total Debt/Equity
N/A
Revenue/Share
0.09 USD as % of share price

Fundamentals

DNTH
Capitalization
1.85B
P/E Ratio
3.24
Risk (Beta)
N/A
Dividend Yield
N/A
Total Cash
403M
Total Cash/Share
9.39
Total Debt
1.29M
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0.09%
Revenue
3.08M
ROE
N/A
Book Value
546M
P/B Ratio
3.39
Cash Flow
N/A
Earnings
-3.5
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
43K
Current Ratio
17.35
Current Revenue Per Employee
5076.92
Dividends Per Share - Security
N/A
EBITDA
-139.9M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-27.12
Shares Held By Institutions
2.45B
Shares Outstanding - Current
42.9M
Total Liabilities
31M
Total Volume MTD
N/A
Value
-1
Gain YTD
97.936
View a ticker or compare two or three
DNTH
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
7 Times Square
Phone
+1 929 999-4055
Employees
53
Web
https://www.dianthustx.com